Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025. This appointment recognises Dr Ochuba’s significant contributions to clinical research and her leadership within the Medical Directorate.

Dr Ochuba joined Richmond in 2022, bringing with her a strong foundation in general medicine and a passion for early-phase research. Since then, she has played a central role in the delivery of complex trials involving both healthy volunteers and patient populations — demonstrating scientific rigour and an unwavering commitment to participant safety.

Dr Ochuba commented:
“I’m honoured to take on the role of Associate Medical Director. My time at Richmond has allowed me to contribute to pioneering clinical research that directly impacts patient care. I look forward to continuing to support our teams as we advance innovative approaches in trial design and delivery.”

Dr Ulrike Lorch, Chief Medical Director, added:
“We are very pleased to acknowledge Dr Ochuba’s promotion, a reflection of her deep commitment to clinical excellence and the integrity of our research. Her measured and thoughtful leadership, combined with a collaborative approach, continues to strengthen our Medical Directorate. Her contributions are very much appreciated and valued.”

This promotion underscores Richmond Pharmacology’s commitment to recognising and developing clinical talent. Dr Ochuba’s expanded role will help further strengthen our capabilities as a leading early-phase CRO delivering complex studies with precision, achieving faster answers for our sponsors and bringing hope to patients.

ENDS

Media Contact:
Linda Rose, Denhams Digital
linda@denhams.digital

07788 592842

About Richmond Pharmacology:

We live in an age of hope. Advances in biomedical science mean that patients with once untreatable conditions can start believing in life again. At Richmond Pharmacology these breakthroughs give our clinical trials a profound sense of urgency. The faster we help our sponsors take their ground-breaking therapies to market, the faster we turn hopes into real answers for patients. We believe in speed without compromise either to our own exceptional science or the safety of patients. We reap the advantages of our London location and our extensive patient database. Above all, speed demands clarity, discipline, accuracy and consistency, perfected over 24 years in the clinical trials business. Every detail of every trial process needs to be right first time.